News |  Disclaimer |  Contact |  Sitemap |  Privacy Notice | 
About us  |   Business Development  |   Territories  |   Partners  |  
Ewopharma is launching the orphan drug Raxone

Ewopharma is strengthening its orphan business and has signed an agreement with Santhera to launch Raxone for the treatment of Leber's Hereditary Optic Neuropathy (LHON) in Central and Eastern Europe. LHON is a heritable genetic disease causing blindness usually leading to permanent bilateral blindness within a few months. The disease it is typically diagnosed in young, otherwise healthy men and Santhera’s orphan drug is the first approved medicine in this field.
Raxone (idebenone) is a synthetic short-chain benzoquinone and a cofactor for the enzyme NAD(P)H:quinone oxidoreductase (NQO1). It circumvents the complex I defect, reduces and scavenges ROS, restores cellular energy levels in retinal ganglion cells and promotes recovery of visual acuity.
Santhera is a Swiss specialty pharmaceutical company focusing on products for the treatment of orphan mitochondrial and neuromuscual diseases.
To read the full press release, please click here.